NBIX - Neurocrine Biosciences, Inc.
| Previous Close | 103.81 |
| Open | 104.15 |
| Bid | 94.79 x 100 |
| Ask | 109.00 x 100 |
| Day's Range | 103.19 - 105.24 |
| 52 Week Range | 46.72 - 106.26 |
| Volume | 376,819 |
| Avg. Volume | 636,953 |
| Market Cap | 9.298B |
| Beta | 2.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.20 |
| Earnings Date | Jul 31, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 110.89 |
Market Realist•5 days agoWhy Tonix Pharmaceuticals Stock Soared Today
Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.
- PR Newswire•11 days ago
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Tuesday, July 31 SAN DIEGO , July 10, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial ...
Market Realist•12 days agoWhy Analysts are Mostly Positive On Acceleron Pharma
After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.
Markit•15 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- ACCESSWIRE•17 days ago
Free Technical Reports on Novavax and Three Additional Biotech Equities
WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.
- Motley Fool•25 days ago
3 Biotech Stocks With Major Potential Catalysts in July
FDA approvals next month could be huge for these biotech stocks.
- TheStreet.com•last month
5 Stocks That Are Screaming Buys Right Now
Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.
Market Realist•last monthVersartis Stock and Its Consistent Rise in the Week Ended June 8
Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.
- PR Newswire•last month
Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego
SAN DIEGO, June 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a San Diego based biotechnology company focused on neurological and endocrine related disorders, is proud to announce that Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences, received the Entrepreneur Of The Year® 2018 Award in the Life Sciences category in San Diego . The EY awards program recognizes entrepreneurs whose ingenuity, spirit of innovation and discipline have driven their companies' success, transformed their industries and made a positive impact on their communities.
Markit•last monthSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Simply Wall St.•2 months ago
What You Must Know About Neurocrine Biosciences Inc’s (NASDAQ:NBIX) Financial Strength
Mid-caps stocks, like Neurocrine Biosciences Inc (NASDAQ:NBIX) with a market capitalization of US$8.60B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
- ACCESSWIRE•2 months ago
Free Technical Insights on OPKO Health and Three Other Biotech Stocks
Stock Research Monitor: NBIX, NVAX, and ONTX LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Fred's, Nexstar Broadcasting Group, CNO Financial Group, Neurocrine Biosciences, Kosmos Energy, and Loews — New Research Emphasizes Economic Growth
NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fred's, ...
- PR Newswire•2 months ago
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Live Audio Webcast Will be on May 15, 2018 SAN DIEGO , May 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference ...
- Motley Fool•2 months ago
3 Top Biotech Stocks to Buy in May
Looking for a few timely buys in the biotech space? Give these gems a closer look.
- PR Newswire•2 months ago
Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics
SAN DIEGO, May 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), providing valuable insight into the impact of involuntary movements on the quality of life of patients taking antipsychotic medication. TD is a condition that is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, which may be disruptive and negatively impact patients.
- Zacks Small Cap Research•3 months ago
NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth
By David Bautz, PhD NASDAQ:NBIX INGREZZA® Launch Continues to go Well On April 30, 2018, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced financial results for the first quarter of 2018 and provided ...
- PR Newswire•3 months ago
Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting
SAN DIEGO, May 2, 2018 /PRNewswire/ -- Neurocrine Biosciences Inc. (NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD). This study is designed to better understand the potentially broad reaching impact of symptoms of possible TD on patients treated with antipsychotic medications.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMT
Q1 2018 Neurocrine Biosciences Inc Earnings Call
- Benzinga•3 months ago
Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...
- Associated Press•3 months ago
Neurocrine: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 47 cents. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
- PR Newswire•3 months ago
Neurocrine Biosciences Reports First Quarter 2018 Financial Results
INGREZZA® (valbenazine) First Quarter Net Product Sales of $71.1 Million with Approximately 12,500 TRx Strong INGREZZA Demand Leads to Expansion of Sales Force Increased Investment in Tourette Syndrome ...
- ACCESSWIRE•3 months ago
Neurocrine Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 30, 2018 at 5:00 PM Eastern ...
- PR Newswire•3 months ago
AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
- Seven presentations of elagolix data highlight AbbVie's research in endometriosis and uterine fibroids - Primary and secondary efficacy and safety data to be presented from two extension Phase 3 studies ...
